MAIA Biotechnology Poster Presentation at ASCO 2024 Annual Meeting

MAIA Biotechnology Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, has announced that their Phase 2 THIO-101 clinical trial will be featured in a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. The event will take place from May 31 to June 4, 2024, in Chicago, Illinois. The poster, which will showcase updated efficacy results from the THIO-101 trial, is scheduled for presentation on June 3, 2024, between 1:30 PM and 4:30 PM CST.

The THIO-101 clinical trial is a multicenter, open-label, dose-optimization study that evaluates the telomere-targeting agent THIO in conjunction with cemiplimab for patients with advanced non-small cell lung cancer (NSCLC). The abstract for this study, titled “A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results,” has garnered attention and will be included in the ASCO 2024 Annual Meeting.

Dr. Vlad Vitoc, the Chairman and Chief Executive Officer of MAIA, expressed pride in participating in ASCO's 2024 Annual Meeting, citing it as the most important global gathering of oncology professionals. Dr. Vitoc emphasized the significance of presenting new efficacy results from the THIO-101 trial and highlighted the innovative telomere-targeting science behind THIO, which is unique in its field of clinical development.

The abstract will be available online on the ASCO Annual Meeting website a week before the conference begins. Additionally, the poster will be published on MAIA Biotechnology's official website on the day of the presentation.

The 2024 ASCO Annual Meeting promises a comprehensive program with more than 200 sessions and 5,000 posters under the theme, “The Art and Science of Cancer Care: From Comfort to Cure.” This annual event is a pivotal platform for oncology professionals to share the latest advancements in cancer research and treatment.

Founded in 1964, ASCO is the leading professional organization dedicated to supporting physicians and oncology professionals in their mission to provide high-quality care for cancer patients. ASCO's overarching goal is to conquer cancer through groundbreaking research, education, and the promotion of equitable patient care. The organization envisions a world where cancer can be prevented or cured, ensuring that every survivor leads a healthy life.

MAIA Biotechnology, Inc. stands as a frontrunner in the field of targeted therapy and immuno-oncology. The company is committed to developing and commercializing innovative drugs that offer new mechanisms of action aimed at improving and extending the lives of cancer patients. MAIA’s flagship program, THIO, targets telomeres in cancer cells. Telomeres are protective caps at the end of chromosomes, and their maintenance is crucial for cancer cell survival. THIO, as a telomere-targeting agent, is being developed for the treatment of NSCLC patients with telomerase-positive cancer cells, making it a potential first-in-class treatment in this domain.

The upcoming presentation at the ASCO 2024 Annual Meeting marks a significant milestone for MAIA Biotechnology as the company continues to advance its promising therapies through clinical development. This event will offer a platform for MAIA to share critical updates with the global oncology community, fostering collaboration and innovation in the fight against cancer.